title: Safety of ergotamine-ergic pharmacologic stress echocardiography for vasospasm testing in the echo lab: 14 year experience on 478 tests in 464 patients.
abstract: BACKGROUND
  The safety of ergonovine/ergometrine stress testing for coronary vasospasm when performed outside the cath lab has vigorously been questioned. The aim of this study was to assess the value of ergonovine/ergometrine stress testing performed in the echo lab.
  
  
  METHODS
  We retrospectively reviewed the data prospectively collected in the echo lab of the Institute of Clinical Physiology of Pisa (Italy) from January 1, 1985, to October 1, 1998, on 478 tests performed on 464 patients with either ergonovine or ergometrine stress echo testing. By selection, all patients had history of chest pain, consistent with vasospastic angina, negative or ambiguous exercise stress testing, and normal or near normal resting left ventricular function. Ergonovine or ergometrine maleate was injected up to a total cumulative dosage of 0.35 mg, under continuous 12 lead ECG and two-dimensional echo monitoring.
  
  
  RESULTS
  There were no death, myocardial infarction, ventricular fibrillation or III degree atrioventricular block. One patient had non-sustained ventricular tachycardia associated with transient ST segment elevation 30 min after the test. Two patients had II degree atrioventricular block, associated with positive echocardiography test and promptly reversed by nitrate administration. Transient regional myocardial dysfunction occurred in 74 patients (15%). Limiting ischemia-independent side effects were present in 13 patients (3%): hypotension in 1, arterial hypertension in 5, nonsustained ventricular tachycardia in 2, and nausea/vomiting in 5. The overall feasibility was 97%.
  
  
  CONCLUSIONS
  Pharmacological stress echocardiography with either ergonovine or ergometrine is highly feasible and can be safely performed in the echo lab in properly selected patients in whom coronary vasospasm is suspected. It is often the only way to document coronary vasospasm otherwise missed by conventional noninvasive stress test and even by coronary angiography.
authors.affiliation: Istituto di Fisiologia Clinica del CNR, Pisa.
authors.forename: A
authors.initials: A
authors.lastname: Djordjevic-Dikic
authors.forename: A
authors.initials: A
authors.lastname: Varga
authors.forename: O
authors.initials: O
authors.lastname: Rodriguez
authors.forename: M
authors.initials: M
authors.lastname: Morelos
authors.forename: R
authors.initials: R
authors.lastname: Sicari
authors.forename: B
authors.initials: B
authors.lastname: Del Negro
authors.forename: M A
authors.initials: MA
authors.lastname: Morales
authors.forename: C
authors.initials: C
authors.lastname: Carpeggiani
authors.forename: E
authors.initials: E
authors.lastname: Picano
mesh_terms: D017023:Coronary Angiography; D003327:Coronary Disease / Q000175:diagnosis*; D003329:Coronary Vasospasm / Q000175:diagnosis*; D004452:Echocardiography / Q000379:methods*; D004874:Ergonovine; D005080:Exercise Test; D005260:Female; D006801:Humans; D008297:Male
chemical_list: D004874:Ergonovine